Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Fisher, G. A., Pommier, R. F., Wolin, E. M., Kunz, P. L., Liyanage, N., Lowenthal, S., Mirakhur, B., Shaheen, M. F., Vinik, A. AMER SOC CLINICAL ONCOLOGY. 2017

View details for DOI 10.1200/JCO.2017.35.15_suppl.4088

View details for Web of Science ID 000411895708172